Abstract:Epidemiologic and experimental animal studies have shown that stress can alter tumor growth and that adrenergic fibers from the sympathetic nervous system, acting through stromal beta2 adrenergic receptors, promote tumor cell survival during the initial phases of cancer development. Recent epidemiological data suggest that beta blocker intake improves survival of prostate cancer patients. Hypertension and high blood pressure have been suggested to increase likelihood of prostate cancer development, suggesting that the use of beta blockers in these patients could reduce prostate cancer risk. Signaling mediated by beta adrenergic receptors promotes neuroendocrine differentiation in the LNCaP prostate cancer cell line. Although neuroendocrine cells are a minor population in the epithelial compartment of normal prostate glands, the population of neuroendocrine-like cells that express markers such as SYN, Bcl-2, Dll-3, and AMACR correlates with cancer progression, androgen-independent state, and poor prognosis in prostate cancer patients. As recent studies show that an increase in neuroendocrine cell density occurs before development of benign prostatic hyperplasia, a non-lethal disease affecting the transition zone, in hypertensive rats, we investigated whether neuroendocrine differentiation is associated with benign prostatic hyperplasia. Our results showed that isobutyl-methyl-xanthine, which blocks cAMP degradation, and forskolin, an adenylate cyclase activator, triggered sustained activation of the cAMP/PKA pathway and led to an increase in neuroendocrine differentiation markers in BPH-1 cells, which are a benign prostatic hyperplasia cell line. Similar results were observed by combining the beta adrenergic receptors agonist isoproterenol with forskolin. The same treatments reduced BPH-1 cell proliferation rates by 40% and 60%, respectively. Effects on AMACR and SYN expression and cell proliferation were fully reversed by the β2 blocker carvedilol. These data suggest that beta adrenergic receptors are linked to the development of neuroendocrine-like cells and benign prostatic hyperplasia. As 20% of the prostate cancer tumors occur in this zone, this observation warrants further investigation.

The Influence of Neuroendocrine Differentiation on the Growth and Androgen Receptor Expression of Prostate Carcinoma Cells

Changes of Intracellular Cholesterol Metabolism in Neuroendocrine Differentiation of Prostate Cancer and Their Significance

The Relationship Between Neuroendocrine Differentiated Prostate Carcinoma and Drug-Resistance to Endocrine Therapy

Advances in the Research of the Relationship between Neuroendocrine Differentiation and Prostate Cancer

Neuroendocrine Differentiation is Involved in Chemoresistance Induced by EGF in Prostate Cancer Cells.

A preliminary study of the effects of breast cancer overexpressed gene 1 on neuroendocrine differentiation in prostate cancer cell

Comprehensive analysis of androgen receptor status in prostate cancer with neuroendocrine differentiation

Molecular mechanisms of neuroendocrine differentiation in prostate cancer progression

Impact of short-term neoadjuvant hormonal treatment on neuroendocrine differentiation in prostate carcinoma

The Crosstalk of Long Non-Coding RNA and MicroRNA in Castration-Resistant and Neuroendocrine Prostate Cancer: Their Interaction and Clinical Importance

Androgen-deprivation Therapy-Induced Aggressive Prostate Cancer with Neuroendocrine Differentiation

Advances in neuroendocrine prostate cancer research: From model construction to molecular network analyses

Molecular Aspects Of Prostate Cancer With Neuroendocrine Differentiation

Molecular model for neuroendocrine prostate cancer progression

Effect of microRNA-148a on neuroendocrine differentiation of human prostate cancer cell line LNCaP

Study on the effect of PEDF peptide 44-mer on differentiation of prostate cancer cell line PC-3

MiR-221 Expression Affects Invasion Potential of Human Prostate Carcinoma Cell Lines by Regulating DVL2

Influence of Abiraterone Acetate on Neuroendocrine Differentiation in Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer

Neuroendocrine Differentiation in Prostate Cancer Requires ASCL1

In vitro neuroendocrine differentiation of BPH-1 cells under beta2 adrenergic receptor stimulation

Endocrine and paracrine characteristics of neuroendocrine prostate cancer